Copyright © 2015, Evaluate Ltd, All rights reserved.
Budget-Busters: The Shift to High-Priced Innovator Drugs in the USA
Top 100 USA Drug Pricing Median Jumped Seven-Fold to $9,400 in 2014


In the five years leading up to 2014 the US market saw a fundamental shift in spending trends towards high-priced medicines, which treat substantially smaller patient populations.

Based on an analysis of the Top 100 selling drugs in the USA, the report Budget-Busters: The Shift to High-Priced Innovator Drugs in the USA reveals that: 

The median price of the Top 100 drugs increased from $1,260 in 2010 to $9,400 in 2014, representing a seven-fold increase

The median patient population size served by a Top 100 drug in 2014 was 146,000, down from 690,000 in 2010

There were seven treatments priced in excess of $100,000 per patient per year in 2014, versus four in 2010 

Download your free copy of this report by confirming your details on the opposite form.

This report was derived from Evaluate’s EvaluatePharma USA Sales, Volume and Pricing Analysis, which is available in the service. This content delivers an integrated, single source for USA sales, volume and pricing providing customers with a clear picture of their markets and their competitors when it comes to price.